Natus Medical Announces 2012 Third Quarter Financial Results
Natus Medical Incorporated (Nasdaq:BABY) today announced financial results for the three and nine months ended September 30, 2012.
For the third quarter ended September 30, 2012, the Company reported revenue of $80.7 million, compared to $51.3 million in the comparable quarter of the previous year. Net loss was $1.9 million, or a net loss of $0.07 per share, compared with net income of $154,000 or $0.01 per diluted share for the third quarter of 2011.
For the nine months ended September 30, 2012, the Company reported revenue of $201.2 million, compared to $168.5 million in the comparable period of the previous year. Net loss was $1.1 million, or $0.04 per share, compared with net income of $5.6 million, or $0.19 per diluted share, for the nine months ended September 30, 2011.
The Company reported non-GAAP earnings per share of $0.15 per diluted share for the third quarter of 2012 compared to $0.07 per diluted share for the third quarter of 2011, and $0.33 per diluted share for the nine months ended September 30, 2012, compared to $0.34 per diluted share for the same period in the previous year.
“I am pleased with our third quarter results as our non-GAAP earnings exceeded our expectations and revenue was in line with our guidance,” said Jim Hawkins, Chief Executive Officer of the Company. “During the quarter we completed the acquisition of the Nicolet business from CareFusion. This is the most significant acquisition in the history of the Company. Natus is now the leading provider of products into the worldwide neurodiagnostic market, with market-leading positions in EEG, EMG, and PSG technologies in both the United States and abroad,” added Hawkins. “In the third quarter we also initiated the reorganization of the Company into two Strategic Business Units: Natus Newborn Care and Natus Neurology. As we drive Natus towards our goal of $500 million in annual revenue, the new SBU structure will give added focus to our business,” said Hawkins.Select the service that is right for you!
COMPARE ALL SERVICESAction Alerts PLUS
TRY IT FREEJim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
TheStreet Quant Ratings
TRY IT FREENew! $49.95/yr
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
Product Features:
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Stocks Under $10
TRY IT FREEDavid Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Dividend Stock Advisor
TRY IT FREEJim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
TRY IT FREEAll of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Product Features:
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Options Profits
TRY IT FREEOur options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV
